NEW YORK, April 2, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Amgen Inc. (NASDAQ: AMGN), Abbott Laboratories (NYSE: ABT), Express
Scripts Holding Company (NASDAQ: ESRX), Zoetis Inc. (NYSE: ZTS),
and Edwards Lifesciences Corp. (NYSE: EW). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Amgen Inc. Analyst Notes
On March 30, 2014, Amgen Inc.
(Amgen) released new detailed data from two Phase 3 pivotal studies
that showed treatment with its novel investigational
cholesterol-lowering medication, evolocumab (AMG 145), resulted in
a statistically significant reduction in low-density lipoprotein
cholesterol (LDL-C). The data showed that the drug showed reduction
in LDL cholesterol of 37% - 39%, compared to ezetimibe in patients
with high cholesterol who cannot tolerate statins. Compared to
those given placebo, the drug resulted in reduction in LDL of 55% -
76%. The results of the two studies of Amgen's evolocumab,
presented at the American College of Cardiology meeting in
Washington, showed that the drug
will help patients who are on a moderate or high-intensity statin
and not adequately controlled, as well as patients who cannot
tolerate statins and are in need of an alternate treatment option
to help lower their LDL cholesterol levels. According to the
Centers for Disease Control and Prevention, more than 71 million
American adults have high LDL-C, or "bad" cholesterol. The positive
study results were welcomed by investors as the stock of Amgen
gained 2.31% to close at $123.34 on
March 31, 2014. The full analyst
notes on Amgen Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04022014/AMGN/report.pdf
--
Abbott Laboratories Analyst Notes
On March 28, 2014, Abbott
Laboratories (Abbott) announced that the U.S. Food and Drug
Administration (FDA) has approved the Company's Supera Peripheral
Stent System that treats people with blocked blood vessels in the
upper leg caused by peripheral artery disease (PAD). The approval
of Supera Peripheral Stent System is based on data from the SUPERB
clinical trial, which showed that the Supera stent proved highly
effective in opening up blocked blood vessels in the upper leg,
even in difficult cases. Also, it observed that during the first
year after treatment with the Supera stent, there were no stent
fractures, and at two years there was a very low stent fracture
rate of 0.5%. The approval gives Abbott rapid entry into one of the
fastest-growing segments of the peripheral stent market. Abbott
expanded its product portfolio with the Supera stent, which already
has a CE mark in Europe, through
the acquisition of IDEV Technologies in August 2013. The full analyst notes on Abbott
Laboratories are available to download free of charge at:
http://www.AnalystsReview.com/04022014/ABT/report.pdf
--
Express Scripts Holding Company Analyst Notes
Express Scripts Holding Company (Express Scripts) posted on its
Events calendar that the Company will hold its Annual Shareholder
Meeting on May 7, 2014 at
8:00 a.m. CT at the Company's
principal Executive Offices at One Express Way, Saint Louis, Missouri. Express Scripts
is headquartered in St. Louis, and
provides integrated pharmacy-benefit management services, including
network-pharmacy claims processing, home delivery, specialty
benefit management, benefit-design consultation, drug-utilization
review, formulary management, and medical and drug data analysis
services. The full analyst notes on Express Scripts Holding Company
are available to download free of charge at:
http://www.AnalystsReview.com/04022014/ESRX/report.pdf
--
Zoetis Inc. Analyst Notes
On March 26, 2014, Zoetis Inc.
(Zoetis) announced its Q2 2014 dividend of $0.072 per share payable on June 2, 2014 to holders of record on April 28, 2014. This dividend represents an
increase of 11% from the quarterly dividend rate paid by animal
health company in 2013. The stock of the Company has slipped 11.42%
in Q1 2014 amidst weaker-than-expected full-year 2014 guidance. The
Company, which swung to profit in Q4 2013 with net income of
$105 million versus net loss of
$10 million in Q4 2012, reported a
full-year 2014 guidance that was below analysts' estimates polled
by Reuters. For full year 2014, Zoetis expects revenues in the
range of $4.65 billion to $4.75
billion, and EPS in the range of $1.15 to $1.21 per share. The full analyst notes
on Zoetis Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04022014/ZTS/report.pdf
--
Edwards Lifesciences Corp. Analyst Notes
On March 30, 2014, Bloomberg
reported that Edwards Lifesciences Corp.'s (Edwards) second
generation Sapien XT, which is used to repair a calcified aortic
valve in the heart, performed better than the closest rival's
device in a head-to-head comparison. Intensifying the race to
acquire a developing market for heart valves that can be inserted
without open-heart surgery, a new group of researchers found that
Edwards' Sapien XT had about the same death rate as the
competitor's device, and was easier to insert. Bloomberg further
reported that the German study of 241 patients concluded that
doctors were able to successfully implant Sapien XT in 96% of
patients, compared with 78% for the rival's device. The full
analyst notes on Edwards Lifesciences Corp. are available to
download free of charge at:
http://www.AnalystsReview.com/04022014/EW/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Ananya
Ghosh, a CFA charterholder. However, we are only human and
are prone to make mistakes. If you notice any errors or omissions,
please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Ananya Ghosh, CFA,
has only reviewed the information provided by Analysts Review in
this article or report according to the Procedures outlined by
Analysts Review. Analysts Review is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Analysts Review